首页 > 最新文献

Neurologia Argentina最新文献

英文 中文
Relevamiento de residencias y concurrencias de neurología en Argentina 阿根廷神经病学住院医师和主治医师调查
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1016/j.neuarg.2023.12.001
Josefina Seguí , Agustina Piedrabuena , Matías Alet

Introduction

In Argentina, physicians can obtain specialization certification through a university postgraduate program, courses provided by recognized medical associations or through a residency or concurrence. Neurologists constitute a small percentage of specialists, with only 0.67% of the available slots in the unique exam allocated to neurology. Accurate data regarding the current situation of training centers in this specialty is lacking. The objective of this study is to assess the current status of neurology residencies and concurrencies in our country.

Materials and methods

Descriptive observational study. Data were collected on institutions offering neurology services and training in the country. A representative from each institution was contacted and administered a questionnaire regarding the presence and number of residents, concurrents, chief resident, resident instructor, with a breakdown by year of training. Information on membership in the Argentine Neurological Society was also obtained.

Results

A total of 52 centers with neurology residency and/or concurrence programs were surveyed. 61.5% (n = 32) were located in the City of Buenos Aires (CABA) and the Province of Buenos Aires (PBA). The total number of residents was 222, with 49 concurrents; 70.8% were undergoing training in CABA (n = 146) and PBA (n = 46). The 71.2% of the centers were public institutions (n = 37), encompassing 69.4% of neurologists in training. Only 37.5% of professionals (n = 116) were members of the Argentine Neurological Society.

Conclusion

We observed a significant disparity in the geographical distribution of neurology training programs in Argentina, contributing to the shortage of neurologists in less populated areas. A collaborative and periodic survey is needed to improve the distribution of future neurologists in the country.

导言在阿根廷,医生可以通过大学研究生课程、公认的医学协会提供的课程或通过住院医师资格考试或并轨考试获得专业认证。神经科医生在专科医生中所占比例很小,在唯一考试中,只有 0.67% 的名额分配给了神经科。有关该专业培训中心现状的准确数据还很缺乏。本研究的目的是评估我国神经病学住院医师培训和并行培训的现状。研究收集了国内提供神经病学服务和培训的机构的数据。我们联系了每个机构的一名代表,并对其进行了问卷调查,调查内容包括住院医师、兼职医师、总住院医师、住院医师导师的人数和存在情况,并按培训年份进行了分类。此外,还获得了有关阿根廷神经病学协会会员的信息。结果 共调查了 52 家拥有神经病学住院医师和/或住院医师培训项目的中心,其中 61.5%(n = 32)的中心拥有神经病学住院医师和/或住院医师培训项目。61.5%(n = 32)的中心位于布宜诺斯艾利斯市(CABA)和布宜诺斯艾利斯省(PBA)。住院医师总数为 222 人,其中有 49 名住院医师;70.8% 的住院医师在布宜诺斯艾利斯市(146 人)和布宜诺斯艾利斯省(46 人)接受培训。71.2%的培训中心为公立机构(37 家),其中 69.4% 的神经科医生正在接受培训。只有 37.5% 的专业人员(n = 116)是阿根廷神经病学协会的会员。结论我们发现阿根廷神经病学培训项目的地理分布存在显著差异,导致人口较少地区的神经病学医生短缺。有必要开展定期合作调查,以改善阿根廷未来神经科医生的分布状况。
{"title":"Relevamiento de residencias y concurrencias de neurología en Argentina","authors":"Josefina Seguí ,&nbsp;Agustina Piedrabuena ,&nbsp;Matías Alet","doi":"10.1016/j.neuarg.2023.12.001","DOIUrl":"10.1016/j.neuarg.2023.12.001","url":null,"abstract":"<div><h3>Introduction</h3><p>In Argentina, physicians can obtain specialization certification through a university postgraduate program, courses provided by recognized medical associations or through a residency or concurrence. Neurologists constitute a small percentage of specialists, with only 0.67% of the available slots in the unique exam allocated to neurology. Accurate data regarding the current situation of training centers in this specialty is lacking. The objective of this study is to assess the current status of neurology residencies and concurrencies in our country.</p></div><div><h3>Materials and methods</h3><p>Descriptive observational study. Data were collected on institutions offering neurology services and training in the country. A representative from each institution was contacted and administered a questionnaire regarding the presence and number of residents, concurrents, chief resident, resident instructor, with a breakdown by year of training. Information on membership in the Argentine Neurological Society was also obtained.</p></div><div><h3>Results</h3><p>A total of 52 centers with neurology residency and/or concurrence programs were surveyed. 61.5% (<em>n</em> <!-->=<!--> <!-->32) were located in the City of Buenos Aires (CABA) and the Province of Buenos Aires (PBA). The total number of residents was 222, with 49 concurrents; 70.8% were undergoing training in CABA (<em>n</em> <!-->=<!--> <!-->146) and PBA (<em>n</em> <!-->=<!--> <!-->46). The 71.2% of the centers were public institutions (<em>n</em> <!-->=<!--> <!-->37), encompassing 69.4% of neurologists in training. Only 37.5% of professionals (<em>n</em> <!-->=<!--> <!-->116) were members of the Argentine Neurological Society.</p></div><div><h3>Conclusion</h3><p>We observed a significant disparity in the geographical distribution of neurology training programs in Argentina, contributing to the shortage of neurologists in less populated areas. A collaborative and periodic survey is needed to improve the distribution of future neurologists in the country.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 9-14"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139456960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tratamiento de la esclerosis múltiple: situación a octubre del 2020 en los hospitales públicos de Costa Rica 多发性硬化症的治疗:2020 年 10 月哥斯达黎加公立医院的状况
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1016/j.neuarg.2023.10.002
Johana Vásquez-Céspedes , Kenneth Carazo-Céspedes , Huberth Fernández-Morales , Andreina Moraga-López , Juan A. Valverde-Espinoza

Introduction

In recent years, multiple treatments for multiple sclerosis have emerged for both, injectable and oral routes of administration. Most of these medications are currently available in Costa Rica. However, interferons are still the only available treatment in the public health system. An overwhelming administrative procedure is required to justify the purchase of the rest of the options in case they are needed for any specific patient.

Objective

To describe the treatment of multiple sclerosis in Costa Rica.

Patients and methods

A longitudinal, observational and retrospective study of cases with the diagnosis of multiple sclerosis in the Costa Rican public hospital system was carried out between 1990 and December 2017. Drug treatment as of October 2020 was analyzed for those patients who met the 2010 McDonald's criteria.

Results

A total of 448 cases were obtained, of which 437 were under drug treatment. The most frequent used drugs were Interferón β1-a intramuscular (53.6%), Interferón β1-b (21.2%) and Interferón β1-a subcutaneous (7.9%). By 2020, 163 patients (36.4%) had continued with the first medication, meanwhile 274 persons (62.3%) needed a change of drug. Treatment failure was the main cause of change and fingolimod was the main alternative choice. Interferón β1-a intramuscular has a longer time of use and less change rate, while fingolimod and Interferón β1-a subcutaneous are more likely to require change in a shorter period of time.

Conclusion

In Costa Rica, interferons are the most widely used treatments for multiple sclerosis in the public health system. Therapeutic failure is the main reason for changing medication, while fingolimod is the treatment of choice in most cases.

导言 近年来,出现了多种治疗多发性硬化症的药物,包括注射和口服两种给药途径。目前,这些药物中的大多数在哥斯达黎加都能买到。然而,干扰素仍然是公共卫生系统中唯一可用的治疗药物。患者和方法在 1990 年至 2017 年 12 月期间,对哥斯达黎加公立医院系统中确诊为多发性硬化症的病例进行了一项纵向、观察性和回顾性研究。对符合2010年麦克唐纳标准的患者截至2020年10月的药物治疗情况进行了分析。结果共获得448例病例,其中437例正在接受药物治疗。使用最多的药物是β1-a干扰素肌肉注射(53.6%)、β1-b干扰素(21.2%)和β1-a干扰素皮下注射(7.9%)。到 2020 年,163 名患者(36.4%)继续使用第一种药物,274 人(62.3%)需要更换药物。治疗失败是换药的主要原因,而芬戈莫德是主要的替代选择。肌注干扰素β1-a的使用时间较长,换药率较低,而芬戈莫德和β1-a皮下注射干扰素更有可能在较短时间内需要换药。治疗失败是换药的主要原因,而芬戈莫德是大多数病例的首选疗法。
{"title":"Tratamiento de la esclerosis múltiple: situación a octubre del 2020 en los hospitales públicos de Costa Rica","authors":"Johana Vásquez-Céspedes ,&nbsp;Kenneth Carazo-Céspedes ,&nbsp;Huberth Fernández-Morales ,&nbsp;Andreina Moraga-López ,&nbsp;Juan A. Valverde-Espinoza","doi":"10.1016/j.neuarg.2023.10.002","DOIUrl":"10.1016/j.neuarg.2023.10.002","url":null,"abstract":"<div><h3>Introduction</h3><p>In recent years, multiple treatments for multiple sclerosis have emerged for both, injectable and oral routes of administration. Most of these medications are currently available in Costa Rica. However, interferons are still the only available treatment in the public health system. An overwhelming administrative procedure is required to justify the purchase of the rest of the options in case they are needed for any specific patient.</p></div><div><h3>Objective</h3><p>To describe the treatment of multiple sclerosis in Costa Rica.</p></div><div><h3>Patients and methods</h3><p>A longitudinal, observational and retrospective study of cases with the diagnosis of multiple sclerosis in the Costa Rican public hospital system was carried out between 1990 and December 2017. Drug treatment as of October 2020 was analyzed for those patients who met the 2010 McDonald's criteria.</p></div><div><h3>Results</h3><p>A total of 448 cases were obtained, of which 437 were under drug treatment. The most frequent used drugs were Interferón β1-a intramuscular (53.6%), Interferón β1-b (21.2%) and Interferón β1-a subcutaneous (7.9%). By 2020, 163 patients (36.4%) had continued with the first medication, meanwhile 274 persons (62.3%) needed a change of drug. Treatment failure was the main cause of change and fingolimod was the main alternative choice. Interferón β1-a intramuscular has a longer time of use and less change rate, while fingolimod and Interferón β1-a subcutaneous are more likely to require change in a shorter period of time.</p></div><div><h3>Conclusion</h3><p>In Costa Rica, interferons are the most widely used treatments for multiple sclerosis in the public health system. Therapeutic failure is the main reason for changing medication, while fingolimod is the treatment of choice in most cases.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 1-8"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138619521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Revisión sobre nuevos enfoques de terapias de neurorrehabilitación para pacientes con trastornos neurológicos mediante dispositivos de pedaleo 回顾利用脚踏装置为神经系统疾病患者提供神经康复疗法的新方法
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1016/j.neuarg.2024.02.001
Alfredo Lobaina Delgado , Denis Delisle-Rodriguez , Adson Ferreira da Rocha , Elizabeth Salvador Figueroa , Alberto López-Delis

Introduction

Currently there are several neurorehabilitation therapies for people with motor impairments caused by neurological disorders. Therapies based on pedaling devices have stood out for their advantages for the recovery of motor function, the prevention or treatment for respiratory and cardiovascular complications, and the induction of neuroplasticity. The Brain Computer Interface (BCI) systems constitute new approaches to provide a rehabilitation that actively involves the patient in therapy and is capable of controlling robotic devices such as stationary bicycles or motorized pedals with their own neural signals.

Aim

Reflect the current state of BCI systems that use pedaling devices for the therapy of patients with neurological disorders.

Methods

A systematic review was carried out in the PubMed and Science Direct databases and other sources such as IEEEXplore, Sensors magazine and Springer publishing house. Original studies and case reports from the last 10 years based on ICC systems for classification of imaginary pedaling movement from EEG signals were included; in healthy subjects and patients with neurological diseases. Papers that did not show quantitative results from metrics such as accuracy during evaluation were excluded. Risk of bias was assessed using the Critical Appraisal Skills Program (CASP).

Results

8 studies that met all eligibility requirements were included. The population of healthy subjects was 43, compared to 6 patients with cerebrovascular accident (CVA) and spinal cord injury (SCI). One of the current limitations of community ICC studies is the scarcity of subjects for the evaluation of different methodologies. The investigations not only yielded quantitative results regarding the performance of the implemented computational algorithms, but also the cortical effects they have produced during cycling as a rehabilitation therapy.

Discussion

Various authors have shown that treatment with pedaling devices modulates brain and muscle activity. Hence, there are patterns or characteristics during real or imagined pedaling movements. From this information, which can be extracted from surface myoelectric signals (sEMG) or electroencephalography (EEG), it is possible to detect pedaling movement intention, and to control devices for these purposes, many of which are already available in the market.

Conclusion

Research about BCI systems based on the detection of imaginary pedaling movement is recent and has achieved a remarkable performance in classification. Commercial devices have yet to incorporate the use of motor imagery therapy.

导言目前,针对因神经系统疾病导致运动障碍的患者有多种神经康复疗法。基于脚踏装置的疗法在恢复运动功能、预防或治疗呼吸和心血管并发症以及诱导神经可塑性方面具有突出优势。脑计算机接口(BCI)系统是提供康复治疗的新方法,它能让患者主动参与治疗,并能利用自身的神经信号控制固定自行车或电动踏板等机器人设备。方法在 PubMed 和 Science Direct 数据库以及 IEEEXplore、《传感器》杂志和 Springer 出版社等其他来源进行了系统综述。研究对象包括健康受试者和神经系统疾病患者,包括过去 10 年中基于 ICC 系统对脑电信号进行假想蹬踏运动分类的原创研究和病例报告。未显示评估期间准确性等指标量化结果的论文被排除在外。结果8项符合所有资格要求的研究被纳入其中。其中健康受试者43人,脑血管意外(CVA)和脊髓损伤(SCI)患者6人。目前,社区 ICC 研究的局限性之一是用于评估不同方法的受试者很少。这些研究不仅得出了有关已实施计算算法性能的定量结果,还得出了这些算法在作为康复疗法的自行车运动中产生的皮质效应。因此,在真实或想象的踩踏运动中存在着一些模式或特征。这些信息可以从表面肌电信号(sEMG)或脑电图(EEG)中提取,从而可以检测蹬踏运动的意图,并控制用于这些目的的设备,其中许多设备已在市场上销售。商用设备尚未结合使用运动想象疗法。
{"title":"Revisión sobre nuevos enfoques de terapias de neurorrehabilitación para pacientes con trastornos neurológicos mediante dispositivos de pedaleo","authors":"Alfredo Lobaina Delgado ,&nbsp;Denis Delisle-Rodriguez ,&nbsp;Adson Ferreira da Rocha ,&nbsp;Elizabeth Salvador Figueroa ,&nbsp;Alberto López-Delis","doi":"10.1016/j.neuarg.2024.02.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2024.02.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Currently there are several neurorehabilitation therapies for people with motor impairments caused by neurological disorders. Therapies based on pedaling devices have stood out for their advantages for the recovery of motor function, the prevention or treatment for respiratory and cardiovascular complications, and the induction of neuroplasticity. The Brain Computer Interface (BCI) systems constitute new approaches to provide a rehabilitation that actively involves the patient in therapy and is capable of controlling robotic devices such as stationary bicycles or motorized pedals with their own neural signals.</p></div><div><h3>Aim</h3><p>Reflect the current state of BCI systems that use pedaling devices for the therapy of patients with neurological disorders.</p></div><div><h3>Methods</h3><p>A systematic review was carried out in the PubMed and Science Direct databases and other sources such as IEEEXplore, Sensors magazine and Springer publishing house. Original studies and case reports from the last 10 years based on ICC systems for classification of imaginary pedaling movement from EEG signals were included; in healthy subjects and patients with neurological diseases. Papers that did not show quantitative results from metrics such as accuracy during evaluation were excluded. Risk of bias was assessed using the Critical Appraisal Skills Program (CASP).</p></div><div><h3>Results</h3><p>8 studies that met all eligibility requirements were included. The population of healthy subjects was 43, compared to 6 patients with cerebrovascular accident (CVA) and spinal cord injury (SCI). One of the current limitations of community ICC studies is the scarcity of subjects for the evaluation of different methodologies. The investigations not only yielded quantitative results regarding the performance of the implemented computational algorithms, but also the cortical effects they have produced during cycling as a rehabilitation therapy.</p></div><div><h3>Discussion</h3><p>Various authors have shown that treatment with pedaling devices modulates brain and muscle activity. Hence, there are patterns or characteristics during real or imagined pedaling movements. From this information, which can be extracted from surface myoelectric signals (sEMG) or electroencephalography (EEG), it is possible to detect pedaling movement intention, and to control devices for these purposes, many of which are already available in the market.</p></div><div><h3>Conclusion</h3><p>Research about BCI systems based on the detection of imaginary pedaling movement is recent and has achieved a remarkable performance in classification. Commercial devices have yet to incorporate the use of motor imagery therapy.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 31-43"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140160920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Estudio de variables demográficas, clínicas y pronósticas en adultos mayores con status epiléptico: análisis comparativo entre diferentes grupos etarios 患有癫痫状态的老年人的人口统计学、临床和预后变量研究:不同年龄组之间的比较分析。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.1016/j.neuarg.2024.01.001
María Florencia Sica , Carla Agustina Holgado , Lucas Martin Romano , Iván Roa , Lucas Piedrafita , Nicolas Pellice , Nicolas Kokos , Agustina Britos , María Emilia Sanchez , María Macarena Bermejo , Daiana Barrio , Sergio Eduardo Gonorazky , Alejandro Fernández , Pablo Ioli , María Emilia Clement

Introduction

Status epilepticus (SE) is a neurological emergency. Certain clinical features and personal patient history have prognostic utility and could contribute to therapeutic decision-making.

Objectives

To describe the demographic and clinical characteristics in patients ≥ 65 years divided into subgroups. To define predictive and prognostic variables.

Material and methods

A retrospective observational study was conducted on all cases of convulsive (CSE) and non-convulsive (NCSE) SE admitted to the Hospital Privado de Comunidad between 2006 and 2013. Age groups were subcategorized according to the World Health Organization (WHO): 65-74 years (G1), 75-84 years (G2), and ≥ 85 years (G3).

Results

A total of 289 patients with SE aged ≥ 65 years were recorded. 84 patients (29.1%) belonged to G1, 141 (48.8%) to G2, and 64 (22.1%) to G3. Females were the most prevalent gender. G3 had the lowest percentage of epilepsy history (9.4%). There was no difference in the CSE-vs-NCSE ratio between the groups. Cerebrovascular disease (CVD) was the most prevalent presentation in the groups, with a higher low-dose of antiepileptic drugs in G1 (P = .08). 30-day lethality was 46.8% (G3), 30.9% (G1), and 36.2% (G2) (P = .13). G1 patients had a higher recurrence rate (P = .001). The total hospitalization cost was higher for G1 (P = .005).

Conclusion

There is a trend to present SE as the first crisis in G3. SE in the elderly tends to occur without a history of epilepsy. The most frequent acute symptomatic cause is CVD. Age is a poor prognostic factor. Hence, the importance of this study in providing data related to this pathology in older adults.

导言癫痫(SE)是一种神经系统急症。某些临床特征和患者个人病史具有预后作用,有助于治疗决策的制定。材料和方法对 2006 年至 2013 年期间在 Comunidad 私立医院收治的所有惊厥性 SE(CSE)和非惊厥性 SE(NCSE)病例进行了回顾性观察研究。根据世界卫生组织(WHO)对年龄组进行了细分:结果共记录了 289 名年龄≥ 65 岁的 SE 患者。84名患者(29.1%)属于G1,141名(48.8%)属于G2,64名(22.1%)属于G3。患者性别以女性居多。G3 有癫痫史的比例最低(9.4%)。各组之间 CSE 与 NCSE 的比例没有差异。脑血管疾病(CVD)是各组中最常见的病症,G1组患者服用低剂量抗癫痫药物的比例更高(P = .08)。30天致死率分别为46.8%(G3)、30.9%(G1)和36.2%(G2)(P = .13)。G1 患者的复发率更高(P = .001)。G1 的住院总费用更高(P = .005)。老年人 SE 的发生往往没有癫痫病史。最常见的急性症状原因是心血管疾病。年龄是一个不良的预后因素。因此,这项研究在提供老年人这一病理相关数据方面具有重要意义。
{"title":"Estudio de variables demográficas, clínicas y pronósticas en adultos mayores con status epiléptico: análisis comparativo entre diferentes grupos etarios","authors":"María Florencia Sica ,&nbsp;Carla Agustina Holgado ,&nbsp;Lucas Martin Romano ,&nbsp;Iván Roa ,&nbsp;Lucas Piedrafita ,&nbsp;Nicolas Pellice ,&nbsp;Nicolas Kokos ,&nbsp;Agustina Britos ,&nbsp;María Emilia Sanchez ,&nbsp;María Macarena Bermejo ,&nbsp;Daiana Barrio ,&nbsp;Sergio Eduardo Gonorazky ,&nbsp;Alejandro Fernández ,&nbsp;Pablo Ioli ,&nbsp;María Emilia Clement","doi":"10.1016/j.neuarg.2024.01.001","DOIUrl":"10.1016/j.neuarg.2024.01.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Status epilepticus (SE) is a neurological emergency. Certain clinical features and personal patient history have prognostic utility and could contribute to therapeutic decision-making.</p></div><div><h3>Objectives</h3><p>To describe the demographic and clinical characteristics in patients ≥<!--> <!-->65<!--> <!-->years divided into subgroups. To define predictive and prognostic variables.</p></div><div><h3>Material and methods</h3><p>A retrospective observational study was conducted on all cases of convulsive (CSE) and non-convulsive (NCSE) SE admitted to the Hospital Privado de Comunidad between 2006 and 2013. Age groups were subcategorized according to the World Health Organization (WHO): 65-74<!--> <!-->years (G1), 75-84<!--> <!-->years (G2), and ≥<!--> <!-->85<!--> <!-->years (G3).</p></div><div><h3>Results</h3><p>A total of 289 patients with SE aged ≥<!--> <!-->65<!--> <!-->years were recorded. 84 patients (29.1%) belonged to G1, 141 (48.8%) to G2, and 64 (22.1%) to G3. Females were the most prevalent gender. G3 had the lowest percentage of epilepsy history (9.4%). There was no difference in the CSE-vs-NCSE ratio between the groups. Cerebrovascular disease (CVD) was the most prevalent presentation in the groups, with a higher low-dose of antiepileptic drugs in G1 (<em>P</em> <!-->=<!--> <!-->.08). 30-day lethality was 46.8% (G3), 30.9% (G1), and 36.2% (G2) (<em>P</em> <!-->=<!--> <!-->.13). G1 patients had a higher recurrence rate (<em>P</em> <!-->=<!--> <!-->.001). The total hospitalization cost was higher for G1 (<em>P</em> <!-->=<!--> <!-->.005).</p></div><div><h3>Conclusion</h3><p>There is a trend to present SE as the first crisis in G3. SE in the elderly tends to occur without a history of epilepsy. The most frequent acute symptomatic cause is CVD. Age is a poor prognostic factor. Hence, the importance of this study in providing data related to this pathology in older adults.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"16 1","pages":"Pages 15-21"},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139965704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Síntomas gastrointestinales inespecíficos como forma de presentación de polineuropatía amiloidótica familiar PAF-TTR. Reporte de un caso 非特异性胃肠道症状是家族性淀粉样变性多发性神经病 PAF-TTR 的一种表现形式。病例报告
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.10.001
Esteban Leonardo Calabrese, German Victor Ramon Calabrese

Introduction

Familial transthyretin amyloidotic polyneuropathy (FAP-TTR), an autosomal dominant disease. It generally manifests with cardiomyopathy and polyneuropathy, however, gastrointestinal (GI) symptoms are common. We report a patient with AF-TTR and initial GI symptoms.

Clinical case

A 67-year-old man presented with burning neuropathic pain. History, diarrhea alternating with constipation and weight loss, diagnosis of irritable bowel. Physical examination alteration of hot-cold sensitivity tests. Sensorimotor axonal polyneuropathy nerve conduction study. Transthyretin gene analysis heterozygous variant p.Val50Met, PAF-TTR diagnosis.

Conclusions

The non-specificity of GI symptoms at the onset of the condition is a challenge in the diagnostic suspicion of this entity.

导言家族性转甲状腺素淀粉样变性多发性神经病(FAP-TTR)是一种常染色体显性遗传病。它通常表现为心肌病和多发性神经病,但胃肠道(GI)症状也很常见。我们报告了一名患有 AF-TTR 并伴有初期消化道症状的患者。病史:腹泻与便秘交替出现,体重减轻,诊断为肠易激综合征。体格检查冷热敏感试验有变化。感觉运动性轴索多发性神经病神经传导检查。转甲状腺素基因分析p.Val50Met杂合子变异,诊断为PAF-TTR。
{"title":"Síntomas gastrointestinales inespecíficos como forma de presentación de polineuropatía amiloidótica familiar PAF-TTR. Reporte de un caso","authors":"Esteban Leonardo Calabrese,&nbsp;German Victor Ramon Calabrese","doi":"10.1016/j.neuarg.2023.10.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.10.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Familial transthyretin amyloidotic polyneuropathy (FAP-TTR), an autosomal dominant disease. It generally manifests with cardiomyopathy and polyneuropathy, however, gastrointestinal (GI) symptoms are common. We report a patient with AF-TTR and initial GI symptoms.</p></div><div><h3>Clinical case</h3><p>A 67-year-old man presented with burning neuropathic pain. History, diarrhea alternating with constipation and weight loss, diagnosis of irritable bowel. Physical examination alteration of hot-cold sensitivity tests. Sensorimotor axonal polyneuropathy nerve conduction study. Transthyretin gene analysis heterozygous variant p.Val50Met, PAF-TTR diagnosis.</p></div><div><h3>Conclusions</h3><p>The non-specificity of GI symptoms at the onset of the condition is a challenge in the diagnostic suspicion of this entity.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 299-303"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utilidad de la identificación de anticuerpos en miopatías inflamatorias: revisión 炎症性肌病中抗体鉴定的作用:综述
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.11.001
Laura Pirra , Belen Tillard , Paz Zuberhbuler , Elisa Cisneros , Mariana Bendersky , Luciana León Cejas , Florencia Aguirre , Valeria Alvarez , Fabio Barroso , Andrés Berardo , Mariela Bettini , Mariano Borrelli , Marcelo Chaves , Fernando Chloca , José Crespo , Marianna di Egidio , Alberto Dubrovsky , María Alejandra Figueredo , Gisella Gargiulo , Agustín Jáuregui , Eugenia Conti

Introduction

The discovery of specific autoantibodies meant a significant milestone in mainly idiopathic inflammatory myopathies (IIM) diagnosis. This granted serological findings to be taken into account along with traditional ones – as clinical and histopathological – in diagnosis criteria, resulting in a new classification consensus.

Objectives

To describe myositis-specific antibodies (AEM) and myositis-associated antibodies (AAM), to describe methodologies for AEM and AAM identification, to define their utility and convenience in daily clinical practice.

Development

AEMs are classified as follows: anti-aminoacyl-tRNA synthetases (AAS), anti-Mi-2 (nucleosome remodeling deacetylase complex), anti-SRP (signal recognition particle), anti-TIF1γ (transcription intermediary factor 1γ), anti-NXP-2 (Nuclear Matrix Protein 2), anti-MDA5 (Melanoma Differentiation Associated Gene 5), anti-SAE (Small ubiquitin-like modifier activating-enzyme), anti-HMGCR (3-Hydroxy-3-methylglutaryl-CoA reductase) and anti-cN-1A (Cytosolic 5′-nucleotidase 1A) and MAA: anti-PM/Scl (Exosome Protein Complex PM/Scl75/100), anti-U1-RNP (U1 small nuclear RNP), anti-Ku (DNA-PK regulatory subunit), anti-Ro/SSA (Sjögren's syndrome related antigen A).

Conclusions

The incorporation of serological criteria in IIM diagnosis criteria led to a new classification consensus, resulting in the tracing and identification of homogeneous patient populations. Such outline provides an opportunity to improve and empower clinical trials when it comes to determine treatments directed to different patient subgroups.

导言特异性自身抗体的发现是特发性炎症性肌病(IIM)诊断的一个重要里程碑。目的描述肌炎特异性抗体(AEM)和肌炎相关抗体(AAM),描述识别AEM和AAM的方法,确定它们在日常临床实践中的实用性和便利性。发展AEM分类如下:抗氨基酸-tRNA合成酶(AAS)、抗Mi-2(核糖体重塑去乙酰化酶复合物)、抗SRP(信号识别颗粒)、抗TIF1γ(转录中间因子1γ)、抗NXP-2(核基质蛋白2)、抗 MDA5(黑色素瘤分化相关基因 5)、抗SAE(小泛素样修饰激活酶)、抗 HMGCR(3-羟基-3-甲基戊二酰-CoA 还原酶)和抗 N-1A(细胞质 5′-核苷酸酶 1A)以及 MAA:抗PM/Scl(外泌体蛋白复合物PM/Scl75/100)、抗U1-RNP(U1小核RNP)、抗Ku(DNA-PK调节亚基)、抗Ro/SSA(斯约格伦综合征相关抗原A)。结论 将血清学标准纳入 IIM 诊断标准,可达成新的分类共识,从而追踪和识别同质患者群体。在确定针对不同患者亚群的治疗方法时,这种概述为改进和加强临床试验提供了机会。
{"title":"Utilidad de la identificación de anticuerpos en miopatías inflamatorias: revisión","authors":"Laura Pirra ,&nbsp;Belen Tillard ,&nbsp;Paz Zuberhbuler ,&nbsp;Elisa Cisneros ,&nbsp;Mariana Bendersky ,&nbsp;Luciana León Cejas ,&nbsp;Florencia Aguirre ,&nbsp;Valeria Alvarez ,&nbsp;Fabio Barroso ,&nbsp;Andrés Berardo ,&nbsp;Mariela Bettini ,&nbsp;Mariano Borrelli ,&nbsp;Marcelo Chaves ,&nbsp;Fernando Chloca ,&nbsp;José Crespo ,&nbsp;Marianna di Egidio ,&nbsp;Alberto Dubrovsky ,&nbsp;María Alejandra Figueredo ,&nbsp;Gisella Gargiulo ,&nbsp;Agustín Jáuregui ,&nbsp;Eugenia Conti","doi":"10.1016/j.neuarg.2023.11.001","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.001","url":null,"abstract":"<div><h3>Introduction</h3><p>The discovery of specific autoantibodies meant a significant milestone in mainly idiopathic inflammatory myopathies (IIM) diagnosis. This granted serological findings to be taken into account along with traditional ones – as clinical and histopathological – in diagnosis criteria, resulting in a new classification consensus.</p></div><div><h3>Objectives</h3><p>To describe myositis-specific antibodies (AEM) and myositis-associated antibodies (AAM), to describe methodologies for AEM and AAM identification, to define their utility and convenience in daily clinical practice.</p></div><div><h3>Development</h3><p>AEMs are classified as follows: anti-aminoacyl-tRNA synthetases (AAS), anti-Mi-2 (nucleosome remodeling deacetylase complex), anti-SRP (signal recognition particle), anti-TIF1γ (transcription intermediary factor 1γ), anti-NXP-2 (Nuclear Matrix Protein 2), anti-MDA5 (Melanoma Differentiation Associated Gene 5), anti-SAE (Small ubiquitin-like modifier activating-enzyme), anti-HMGCR (3-Hydroxy-3-methylglutaryl-CoA reductase) and anti-cN-1A (Cytosolic 5′-nucleotidase 1A) and MAA: anti-PM/Scl (Exosome Protein Complex PM/Scl75/100), anti-U1-RNP (U1 small nuclear RNP), anti-Ku (DNA-PK regulatory subunit), anti-Ro/SSA (Sjögren's syndrome related antigen A).</p></div><div><h3>Conclusions</h3><p>The incorporation of serological criteria in IIM diagnosis criteria led to a new classification consensus, resulting in the tracing and identification of homogeneous patient populations. Such outline provides an opportunity to improve and empower clinical trials when it comes to determine treatments directed to different patient subgroups.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 288-298"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821917","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valores normativos para el Cuestionario de Quejas Cognitivas para adultos entre 30 y 90 años 30 至 90 岁成年人认知投诉问卷的标准值
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.09.001
Diana Bruno , Veronica Fernandez , Florencia Portillo , Solange Llarena Nuñez

Introduction

The Cognitive Complaints Questionnaire (CCQ) has proven to be a valid and reliable instrument according to expert judgment and concurrent validity analysis with objective measures, to assess people's cognitive complaints. This is important when considering them as a possible indicator of cognitive deterioration. In order to facilitate the interpretation and comparison of the results of the instrument, it is necessary not only that it present good psychometric properties, but also that it be standardized and regulated.

Objective

Generate normative values for the CCQ in a sample of adults between 30 and 90 years of age from Argentine.

Subjects and method

Quantitative approach of instrumental type. The sample included 230 healthy people, residents in Argentina, with no psychiatric or neurological history.

Results

Correlations were observed between the CCQ and age and years of formal education, for this reason the normative values of the CCQ were organized by groups according to age and years of formal education. For age groups were divided into 2, one from 30 to 70 years and the other from 71 to 90 years. And for the years of formal education, 3 groups were formed: less than 7 years, between 7 and 15 years, and more than 15 years. The analysis of the psychometric properties once again yielded very good internal consistency and validity indices. Normative values are presented.

Conclusion

The CCQ is a useful instrument for exploring cognitive complaints.

导言:根据专家的判断和与客观测量方法的并行有效性分析,认知投诉问卷(CCQ)已被证明是一种有效且可靠的工具,可用于评估人们的认知投诉。这对于将其视为认知功能衰退的可能指标非常重要。为了便于解释和比较该工具的结果,不仅需要该工具具有良好的心理测量特性,还需要对其进行标准化和规范化。结果观察到 CCQ 与年龄和正规教育年限之间存在相关性,因此根据年龄和正规教育年限对 CCQ 的标准值进行了分组。年龄组分为两组,一组为 30 至 70 岁,另一组为 71 至 90 岁。正规教育年限分为三组:少于 7 年、7 至 15 年和 15 年以上。心理测量特性分析再次得出了非常好的内部一致性和有效性指数。结论:CCQ 是研究认知投诉的有用工具。
{"title":"Valores normativos para el Cuestionario de Quejas Cognitivas para adultos entre 30 y 90 años","authors":"Diana Bruno ,&nbsp;Veronica Fernandez ,&nbsp;Florencia Portillo ,&nbsp;Solange Llarena Nuñez","doi":"10.1016/j.neuarg.2023.09.001","DOIUrl":"10.1016/j.neuarg.2023.09.001","url":null,"abstract":"<div><h3>Introduction</h3><p>The Cognitive Complaints Questionnaire (CCQ) has proven to be a valid and reliable instrument according to expert judgment and concurrent validity analysis with objective measures, to assess people's cognitive complaints. This is important when considering them as a possible indicator of cognitive deterioration. In order to facilitate the interpretation and comparison of the results of the instrument, it is necessary not only that it present good psychometric properties, but also that it be standardized and regulated.</p></div><div><h3>Objective</h3><p>Generate normative values for the CCQ in a sample of adults between 30 and 90 years of age from Argentine.</p></div><div><h3>Subjects and method</h3><p>Quantitative approach of instrumental type. The sample included 230 healthy people, residents in Argentina, with no psychiatric or neurological history.</p></div><div><h3>Results</h3><p>Correlations were observed between the CCQ and age and years of formal education, for this reason the normative values of the CCQ were organized by groups according to age and years of formal education. For age groups were divided into 2, one from 30 to 70 years and the other from 71 to 90 years. And for the years of formal education, 3 groups were formed: less than 7 years, between 7 and 15 years, and more than 15 years. The analysis of the psychometric properties once again yielded very good internal consistency and validity indices. Normative values are presented.</p></div><div><h3>Conclusion</h3><p>The CCQ is a useful instrument for exploring cognitive complaints.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 271-278"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135849321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relevamiento de recursos disponibles para el manejo de status epiléptico en centros asistenciales en Argentina 阿根廷医疗保健中心癫痫状态管理可用资源调查。
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.08.001
Viviana Ibarra , Cristina Papayannis , María Belén Viaggio , Lucas Romano , Ricardo Bernater , Mónica Perassolo , Vanesa Roig , Analía Calle

Introduction

Status epilepticus (SE) is a neurological emergency that requires prompt diagnosis and treatment due to its high morbidity and mortality. Knowing the availability of local diagnostic and treatment resources is important for improving therapeutic outcomes through effective strategies.

Objective

To assess the resources available for the diagnosis and treatment of SE in hospitals in the Argentine Republic.

Materials and methods

The Epilepsy Working Group of the Argentine Neurological Society distributed a voluntary semi-structured survey to 51 representative centers for the care of patients with SE in July 2021. Information was requested regarding the healthcare model, pharmacological protocols for different phases of SE, and available electroencephalographic resources.

Results

Regarding the early stage of SE, we found that there is adequate availability of antiseizure medications (ASMs) in both public and private centers, with lorazepam being the most commonly chosen drug. Regarding the treatment choice for established SE, we found that phenytoin is the most commonly used in public hospitals, while levetiracetam is the preferred choice in nonpublic hospitals, and this difference is statistically significant (p < 0.0001). There was a low availability of EEG monitoring in both settings, although there was a greater availability of prolonged monitoring in private centers (p = 0.0003).

Conclusion

This study provides information about the available resources in our country for the management of SE and allows for the development of educational and management strategies to improve its diagnosis and treatment.

导言癫痫(SE)是一种神经系统急症,由于其发病率和死亡率都很高,因此需要及时诊断和治疗。了解当地诊断和治疗资源的可用性对于通过有效策略改善治疗效果非常重要。材料和方法阿根廷神经病学学会癫痫工作组于 2021 年 7 月向 51 家具有代表性的 SE 患者护理中心发放了一份自愿性半结构化调查问卷。调查要求提供有关医疗保健模式、SE 不同阶段的药物治疗方案以及可用脑电图资源的信息。结果我们发现,在 SE 的早期阶段,公立和私立中心均可提供充足的抗癫痫药物(ASMs),劳拉西泮是最常用的药物。关于已确诊的 SE 的治疗选择,我们发现公立医院最常用的药物是苯妥英,而非公立医院则首选左乙拉西坦,这一差异具有统计学意义(p < 0.0001)。在这两种情况下,脑电图监测的可用性都很低,但在私立中心,长期监测的可用性更高(p = 0.0003)。
{"title":"Relevamiento de recursos disponibles para el manejo de status epiléptico en centros asistenciales en Argentina","authors":"Viviana Ibarra ,&nbsp;Cristina Papayannis ,&nbsp;María Belén Viaggio ,&nbsp;Lucas Romano ,&nbsp;Ricardo Bernater ,&nbsp;Mónica Perassolo ,&nbsp;Vanesa Roig ,&nbsp;Analía Calle","doi":"10.1016/j.neuarg.2023.08.001","DOIUrl":"10.1016/j.neuarg.2023.08.001","url":null,"abstract":"<div><h3>Introduction</h3><p>Status epilepticus (SE) is a neurological emergency that requires prompt diagnosis and treatment due to its high morbidity and mortality. Knowing the availability of local diagnostic and treatment resources is important for improving therapeutic outcomes through effective strategies.</p></div><div><h3>Objective</h3><p>To assess the resources available for the diagnosis and treatment of SE in hospitals in the Argentine Republic.</p></div><div><h3>Materials and methods</h3><p>The Epilepsy Working Group of the Argentine Neurological Society distributed a voluntary semi-structured survey to 51 representative centers for the care of patients with SE in July 2021. Information was requested regarding the healthcare model, pharmacological protocols for different phases of SE, and available electroencephalographic resources.</p></div><div><h3>Results</h3><p>Regarding the early stage of SE, we found that there is adequate availability of antiseizure medications (ASMs) in both public and private centers, with lorazepam being the most commonly chosen drug. Regarding the treatment choice for established SE, we found that phenytoin is the most commonly used in public hospitals, while levetiracetam is the preferred choice in nonpublic hospitals, and this difference is statistically significant (<em>p</em> &lt; 0.0001). There was a low availability of EEG monitoring in both settings, although there was a greater availability of prolonged monitoring in private centers (<em>p</em> = 0.0003).</p></div><div><h3>Conclusion</h3><p>This study provides information about the available resources in our country for the management of SE and allows for the development of educational and management strategies to improve its diagnosis and treatment.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 261-270"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135607304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Características clínicas y demográficas de los pacientes con enfermedades desmielinizantes en Ecuador 厄瓜多尔脱髓鞘疾病患者的临床和人口特征
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.11.002
Patricio Alexander Merino Aguilera , Edgar Patricio Correa Díaz , Ruth Jimbo Sotomayor , Jorge Rubén Pilco Romero

Introduction

MS and NMOSD are chronic demyelinating diseases mediated by the immune system, related to demyelinating attacks on the brain, optic nerve and spinal cord, which can cause severe disability in young people. In LATAM there is few reports on the demographic and clinical characteristics of both diseases.

Objective

To establish and compare the clinical and demographic characteristics of MS and NMOSD patients.

Materials and methods

This is a descriptive and transversal study which included MS and NMOSD patients who were attended in the Carlos Andrade Marin hospital in Quito, Ecuador. Univariate and multivariate analysis were performed using SPSS.

Results

We included 151 patients with MS and NMOSD, the predominant sex in the two diseases was female, mestizo ethnicity was common in both diseases, higher education was frequent in both conditions specially in MS. The average age was 42.3 years in EM and 49.8 years in TENMO (p < 0.005). Fatigue was more common in MS than NMOSD. There was a predominance of mild disability in EM and moderate disability in TENMO with a mean of EDSS 2.5 and 4.2, respectively (p < 0.005). The presence of comorbidities was infrequent in both diseases.

Conclusión

The clinical and demographic characteristics in our study is very similar to finding around the world. However, the mestizo ethnicity was common in both conditions. We found lower frequency of fatigue, motor and sensory symptoms in comparison with previous reports. NMOSD patients had higher disability than MS patients.

导言多发性硬化症和非小脑性脊髓炎是由免疫系统介导的慢性脱髓鞘疾病,与大脑、视神经和脊髓的脱髓鞘病变有关,可导致年轻人严重残疾。在拉丁美洲和加勒比海地区,关于这两种疾病的人口统计学和临床特征的报道很少。目的确定并比较多发性硬化症和非脱髓鞘性脊髓炎患者的临床和人口统计学特征。材料和方法这是一项描述性横向研究,研究对象包括在厄瓜多尔基多卡洛斯-安德拉德-马林医院就诊的多发性硬化症和非脱髓鞘性脊髓炎患者。使用 SPSS 进行了单变量和多变量分析。结果我们纳入了 151 名多发性硬化症和 NMOSD 患者,这两种疾病的主要性别为女性,混血儿在这两种疾病中都很常见,受过高等教育的人在这两种疾病中都很常见,尤其是多发性硬化症患者。多发性硬化症患者的平均年龄为 42.3 岁,TENMO 患者的平均年龄为 49.8 岁(p < 0.005)。疲劳在多发性硬化症中比在 NMOSD 中更为常见。EM以轻度残疾为主,TENMO以中度残疾为主,EDSS平均值分别为2.5和4.2(p <0.005)。在这两种疾病中,合并症都不常见。然而,混血儿在两种疾病中都很常见。与之前的报告相比,我们发现疲劳、运动和感觉症状的发生率较低。NMOSD患者的致残率高于多发性硬化症患者。
{"title":"Características clínicas y demográficas de los pacientes con enfermedades desmielinizantes en Ecuador","authors":"Patricio Alexander Merino Aguilera ,&nbsp;Edgar Patricio Correa Díaz ,&nbsp;Ruth Jimbo Sotomayor ,&nbsp;Jorge Rubén Pilco Romero","doi":"10.1016/j.neuarg.2023.11.002","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.002","url":null,"abstract":"<div><h3>Introduction</h3><p>MS and NMOSD are chronic demyelinating diseases mediated by the immune system, related to demyelinating attacks on the brain, optic nerve and spinal cord, which can cause severe disability in young people. In LATAM there is few reports on the demographic and clinical characteristics of both diseases.</p></div><div><h3>Objective</h3><p>To establish and compare the clinical and demographic characteristics of MS and NMOSD patients.</p></div><div><h3>Materials and methods</h3><p>This is a descriptive and transversal study which included MS and NMOSD patients who were attended in the Carlos Andrade Marin hospital in Quito, Ecuador. Univariate and multivariate analysis were performed using SPSS.</p></div><div><h3>Results</h3><p>We included 151 patients with MS and NMOSD, the predominant sex in the two diseases was female, mestizo ethnicity was common in both diseases, higher education was frequent in both conditions specially in MS. The average age was 42.3 years in EM and 49.8 years in TENMO (<em>p</em> &lt; 0.005). Fatigue was more common in MS than NMOSD. There was a predominance of mild disability in EM and moderate disability in TENMO with a mean of EDSS 2.5 and 4.2, respectively (<em>p</em> &lt; 0.005). The presence of comorbidities was infrequent in both diseases.</p></div><div><h3>Conclusión</h3><p>The clinical and demographic characteristics in our study is very similar to finding around the world. However, the mestizo ethnicity was common in both conditions. We found lower frequency of fatigue, motor and sensory symptoms in comparison with previous reports. NMOSD patients had higher disability than MS patients.</p></div>","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 279-287"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Profesor Rolando Juvenal Giannaula (16 agosto 1953-26 enero 2023) 罗兰多-胡维纳尔-贾纳乌拉教授(1953 年 8 月 16 日至 2023 年 1 月 26 日)
Q4 Medicine Pub Date : 2023-10-01 DOI: 10.1016/j.neuarg.2023.11.003
{"title":"Profesor Rolando Juvenal Giannaula (16 agosto 1953-26 enero 2023)","authors":"","doi":"10.1016/j.neuarg.2023.11.003","DOIUrl":"https://doi.org/10.1016/j.neuarg.2023.11.003","url":null,"abstract":"","PeriodicalId":39051,"journal":{"name":"Neurologia Argentina","volume":"15 4","pages":"Pages 306-307"},"PeriodicalIF":0.0,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1853002823000708/pdfft?md5=2447638aae94ca0ff206d3e5aaedd2bf&pid=1-s2.0-S1853002823000708-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138821943","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Neurologia Argentina
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1